A Major New Study Confirms: SGLT2 Inhibitors Protect the Kidneys Even After Age 65

A new meta-analysis of more than 5,800 adults aged 65 and older shows that SGLT2 inhibitors significantly slow kidney disease progression, reduce the risk of heart failure and cardiovascular death.